Automated, Low Volume Dynamic Light Scattering Technology to Accelerate Protein Crystallization
Poster Nov 02, 2006
Kevin Jackson and Robert Collins
The quest for solving protein structure largely relies upon X-Ray diffraction, a method requiring crystalline forms of the target protein. Among the many steps comprising structure determination, the process of protein crystallization represents one of the most significant, time-consuming challenges. A new low sample volume, automated dynamic light scattering (DLS) technology has been developed – the DynaPro Plate Reader.
The DynaPro Plate Reader can measure protein samples less than 5 microliters in volume, at less than 1 mg/mL concentrations in 1536 well-plate formats. By analyzing 100’s of samples per day, in an unattended fashion, the DynaPro Plate Reader improves the productivity of vital dynamic light scattering applications in the protein crystallization process: screening proteins for aggregation prior to crystallization trials and solubility screening. More conditions can be explored in less time with less sample, leading to the successful optimization of the protein and/or crystallization conditions.
Bioluminescent Kinase Profiling Systems For Characterizing Small Molecule Kinase InhibitorsPoster
In order to profile compounds against a broad panel of kinases, in-house profiling requires rigorous kinase assay development.READ MORE
Assessment of Oral LISPRO Treatment in Ameliorating Amyloid and Tau Pathology in Transgenic Alzheimer’s Mice ModelPoster
Ionic co-crystals of lithium salicylate with organic proline (LISPRO) showed better safety and pharmacokinetic profile of lithium in plasma and brain of wild-type and transgenic Alzheimer mice model compared to lithium salts.READ MORE
CiPA Phase 2 Study: validation of an automated microelectrode array (MEA) assay of hiPSC-derived cardiomyocyte electrophysiology for cardiac safety evaluationPoster
These results support the use of hSC-CM and MEA technology for preclinical assessment of proarrhythmic risk within the proposed CiPA paradigm, and, more generally, demonstrate that automation of the CM-MEA assay can achieve high reliability and throughput for cardiac risk assessment in vitro.READ MORE